Biotia Announces Advanced "Test to Treat" Offering for Recurrent Urinary Tract Infections

NEW YORK, Sept. 8, 2025 /PRNewswire/ -- Biotia today announced the launch of a new "test to treat" option for patients suffering from recurrent urinary tract infections (UTIs), moving UTI care forward. This solution allows patients to collect a urine sample for more advanced laboratory testing, and receive virtual care from clinicians trained specifically in recurrent UTI treatment – all from the privacy of their home.

This new care pathway addresses the shortcomings of existing UTI diagnostics and treatment. There are an estimated 11 million cases of UTI in the U.S. each year. Most cases are either treated blindly or diagnosed by traditional methods, including through urine culture. However, urine culture fails about 30% of the time and is particularly poor at identifying infections caused by anaerobes, fungi, and fastidious pathogens. This leads to many patients receiving an inaccurate diagnosis and inappropriate treatment – proving especially problematic for recurrent UTI sufferers.

Powered by the BIOTIA-ID Urine Test, this new initiative is increasing access for eligible recurrent UTI patients under clinician care to advanced molecular diagnostics, ensuring accurate diagnosis and guided precision treatment for faster relief.

The BIOTIA-ID Urine Test

Biotia's cutting-edge diagnostic, called the BIOTIA-ID Urine Test, uses next-generation sequencing and artificial intelligence (clinical metagenomics) to detect over 40 key uropathogens and generate insights into antimicrobial resistance (currently research-use-only). The test is available across all 50 U.S. states and is backed by rigorous analytical and clinical validation demonstrating substantial improvement over urine culture. Following testing, patients are able to schedule a virtual visit with a clinician from their telehealth partner, Clinova.Solutions.

"Patients with recurrent or chronic UTIs face significant challenges in obtaining an accurate diagnosis and effective treatment. Instead of enduring repeated doctor visits and lab tests, we provide a streamlined solution: one comprehensive test paired with telehealth consultation to help patients quickly address their symptoms," said Dr. Nagy-Szakal, Chief Medical Officer of Biotia.

Patients can check their eligibility and obtain the BIOTIA-ID Urine Test and treatment by visiting www.biotia.io.

About Biotia
Biotia is a leading precision diagnostics company specializing in clinical metagenomics and AI-driven solutions for infectious disease diagnostics, and is dedicated to improving health outcomes worldwide. To learn more about Biotia, visit www.biotia.io, or connect on Instagram Facebook, and LinkedIn.

Media Contact:
Biotia: +1 (888) 685-2885, [email protected]

SOURCE Biotia, Inc.